102 related articles for article (PubMed ID: 29792135)
1. Modified LDL Immune Complexes and Cardiovascular Disease.
Lopes-Virella MF; Virella G
Curr Med Chem; 2019; 26(9):1680-1692. PubMed ID: 29792135
[TBL] [Abstract][Full Text] [Related]
2. Immune complexes containing malondialdehyde (MDA) LDL induce apoptosis in human macrophages.
Virella G; Wilson K; Elkes J; Hammad SM; Rajab HA; Li Y; Chassereau C; Huang Y; Lopes-Virella M
Clin Immunol; 2018 Feb; 187():1-9. PubMed ID: 28689783
[TBL] [Abstract][Full Text] [Related]
3. Proatherogenic and proinflammatory properties of immune complexes prepared with purified human oxLDL antibodies and human oxLDL.
Virella G; Atchley D; Koskinen S; Zheng D; Lopes-Virella MF;
Clin Immunol; 2002 Oct; 105(1):81-92. PubMed ID: 12483997
[TBL] [Abstract][Full Text] [Related]
4. Pathogenic role of modified LDL antibodies and immune complexes in atherosclerosis.
Lopes-Virella MF; Virella G
J Atheroscler Thromb; 2013; 20(10):743-54. PubMed ID: 23965492
[TBL] [Abstract][Full Text] [Related]
5. Oxidized LDL and AGE-LDL in circulating immune complexes strongly predict progression of carotid artery IMT in type 1 diabetes.
Hunt KJ; Baker N; Cleary P; Backlund JY; Lyons T; Jenkins A; Virella G; Lopes-Virella MF;
Atherosclerosis; 2013 Dec; 231(2):315-22. PubMed ID: 24267245
[TBL] [Abstract][Full Text] [Related]
6. Development of capture assays for different modifications of human low-density lipoprotein.
Virella G; Derrick MB; Pate V; Chassereau C; Thorpe SR; Lopes-Virella MF
Clin Diagn Lab Immunol; 2005 Jan; 12(1):68-75. PubMed ID: 15642987
[TBL] [Abstract][Full Text] [Related]
7. The levels of MDA-LDL in circulating immune complexes predict myocardial infarction in the VADT study.
Lopes-Virella MF; Hunt KJ; Baker NL; Virella G; Moritz T;
Atherosclerosis; 2012 Oct; 224(2):526-31. PubMed ID: 22963984
[TBL] [Abstract][Full Text] [Related]
8. Definition of the immunogenic forms of modified human LDL recognized by human autoantibodies and by rabbit hyperimmune antibodies.
Virella G; Thorpe SR; Alderson NL; Derrick MB; Chassereau C; Rhett JM; Lopes-Virella MF
J Lipid Res; 2004 Oct; 45(10):1859-67. PubMed ID: 15258197
[TBL] [Abstract][Full Text] [Related]
9. Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus.
Lopes-Virella MF; Virella G; Orchard TJ; Koskinen S; Evans RW; Becker DJ; Forrest KY
Clin Immunol; 1999 Feb; 90(2):165-72. PubMed ID: 10080827
[TBL] [Abstract][Full Text] [Related]
10. Immune Complexes and the Risk of CVD in Type 1 Diabetes.
Lopes-Virella MF; Bebu I; Hunt KJ; Virella G; Baker NL; Braffett B; Gao X; Lachin JM;
Diabetes; 2019 Sep; 68(9):1853-1860. PubMed ID: 31217176
[TBL] [Abstract][Full Text] [Related]
11. High levels of AGE-LDL, and of IgG antibodies reacting with MDA-lysine epitopes expressed by oxLDL and MDA-LDL in circulating immune complexes predict macroalbuminuria in patients with type 2 diabetes.
Lopes-Virella MF; Hunt KJ; Baker NL; Virella G;
J Diabetes Complications; 2016; 30(4):693-9. PubMed ID: 26861948
[TBL] [Abstract][Full Text] [Related]
12. Increased levels of autoantibodies against copper-oxidized low density lipoprotein, malondialdehyde-modified low density lipoprotein and cardiolipin in patients with rheumatoid arthritis.
Cvetkovic JT; Wållberg-Jonsson S; Ahmed E; Rantapää-Dahlqvist S; Lefvert AK
Rheumatology (Oxford); 2002 Sep; 41(9):988-95. PubMed ID: 12209031
[TBL] [Abstract][Full Text] [Related]
13. The Pathogenic Role of the Adaptive Immune Response to Modified LDL in Diabetes.
Virella G; Lopes-Virella MF
Front Endocrinol (Lausanne); 2012; 3():76. PubMed ID: 22715334
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of the humoral immune response to modified LDL.
Lopes-Virella MF; Virella G
Clin Immunol; 2010 Jan; 134(1):55-65. PubMed ID: 19427818
[TBL] [Abstract][Full Text] [Related]
15. Oxidized LDL immune complexes induce release of sphingosine kinase in human U937 monocytic cells.
Hammad SM; Taha TA; Nareika A; Johnson KR; Lopes-Virella MF; Obeid LM
Prostaglandins Other Lipid Mediat; 2006 Mar; 79(1-2):126-40. PubMed ID: 16516816
[TBL] [Abstract][Full Text] [Related]
16. Oxidized LDL immune complexes and coronary artery calcification in type 1 diabetes.
Lopes-Virella MF; Baker NL; Hunt KJ; Lachin J; Nathan D; Virella G;
Atherosclerosis; 2011 Feb; 214(2):462-7. PubMed ID: 21156319
[TBL] [Abstract][Full Text] [Related]
17. Oxidized low-density lipoprotein autoantibodies, chronic infections, and carotid atherosclerosis in a population-based study.
Mayr M; Kiechl S; Tsimikas S; Miller E; Sheldon J; Willeit J; Witztum JL; Xu Q
J Am Coll Cardiol; 2006 Jun; 47(12):2436-43. PubMed ID: 16781371
[TBL] [Abstract][Full Text] [Related]
18. [Proatherogenic effects of immune complexes of human oxLDL in vitro].
Liang ZS; Yang K; Cao Y; Ou-Yang M; Zhang ZH; Li JL; Tang XH; Zhang MX
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2005 Apr; 30(2):202-6. PubMed ID: 15898435
[TBL] [Abstract][Full Text] [Related]
19. Immunoassay of modified forms of human low density lipoprotein in isolated circulating immune complexes.
Virella G; Colglazier J; Chassereau C; Hunt KJ; Baker NL; Lopes-Virella MF
J Immunoassay Immunochem; 2013; 34(1):61-74. PubMed ID: 23323982
[TBL] [Abstract][Full Text] [Related]
20. Disease Activity, Oxidized-LDL Fraction and Anti-Oxidized LDL Antibodies Influence Cardiovascular Risk in Rheumatoid Arthritis.
Nowak B; Madej M; Łuczak A; Małecki R; Wiland P
Adv Clin Exp Med; 2016; 25(1):43-50. PubMed ID: 26935497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
